Evidence map›Paper›PMID 34608231›Full record

ArticleScientific reports2021

Longitudinal urinary biomarkers of immunological activation in covid-19 patients without clinically apparent kidney disease versus acute and chronic failure.

Krzysztof Laudanski, Tony Okeke, Jihane Hajj, Kumal Siddiq, Daniel J Rader, Junnan Wu, Katalin Susztak

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Krzysztof LaudanskiDepartment of Anesthesiology and Critical Care, The University of Pennsylvania, Philadelphia, PA, USA. klaudanski@gmail.com.
Tony OkekeSchool of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.
Jihane HajjSchool of Nursing, Widener University, Philadelphia, PA, USA.
Kumal SiddiqCollege of Arts and Sciences, Drexel University, Philadelphia, PA, USA.
Daniel J RaderDepartment of Genetics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
Junnan WuDepartment of Genetics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
Katalin SusztakDepartment of Genetics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USDrexel University · USWidener University · US

Funding

Role of the Notch Pathway in Kidney InjuryR01DK076077 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATALIN SUSZTAK · 2007 to 2026
$8.0M
Epigenetics of Chronic Kidney DiseaseR01DK087635 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATALIN SUSZTAK · 2009 to 2026
$7.0M
APOL1 associated kidney diseaseR01DK105821 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SUSZTAK, KATALIN · 2016 to 2024
$4.6M
The role of cytosolic nucleotide sensors in inflammatory fibrosisR01DK132630 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SUSZTAK, KATALIN · 2022 to 2025
$2.0M
Epigenetic mediated long-term aberrations in myeloid cells after critical illnessK23GM120630 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI LAUDANSKI, KRZYSZTOF · 2017 to 2020
$783k
NIDDK NIH HHS R01 DK076077NIDDK NIH HHS R01 DK087635NIDDK NIH HHS R01 DK105821NIDDK NIH HHS R01 DK132630NIGMS NIH HHS K23 GM120630
6 · The paper itself

Abstract

Kidney function is affected in COVID-19, while kidney itself modulates the immune response. Here, hypothesize if COVID-19 urine biomarkers level can assess immune activation vs. clinical trajectory. Considering the kidney's critical role in modulating the immune response, we sought to analyze activation markers in patients with pre-existing dysfunction. This was a cross-sectional study of 68 patients. Blood and urine were collected within 48 h of hospital admission (H1), followed by 96 h (H2), seven days (H3), and up to 25 days (H4) from admission. Serum level ferritin, procalcitonin, IL-6 assessed immune activation overall, while the response to viral burden was gauged with serum level of spike protein and αspike IgM and IgG. 39 markers correlated highly between urine and blood. Age and race, and to a lesser extend gender, differentiated several urine markers. The burden of pre-existing conditions correlated with urine DCN, CAIX and PTN, but inversely with IL-5 or MCP-4. Higher urinary IL-12 and lower CAIX, CCL23, IL-15, IL-18, MCP-1, MCP-3, MUC-16, PD-L1, TNFRS12A, and TNFRS21 signified non-survivors. APACHE correlated with urine TNFRS12, PGF, CAIX, DCN, CXCL6, and EGF. Admission urine LAG-3 and IL-2 predicted death. Pre-existing kidney disease had a unique pattern of urinary inflammatory markers. Acute kidney injury was associated, and to a certain degree, predicted by IFNg, TWEAK, MMP7, and MUC-16. Remdesavir had a more profound effect on the urine biomarkers than steroids. Urinary biomarkers correlated with clinical status, kidney function, markers of the immune system activation, and probability of demise in COVID-19.

Indexed as

Acute Kidney InjuryAdultAgedAntigens, CDBiomarkersCA-125 AntigenChemokines, CCCOVID-19Cross-Sectional StudiesFemaleHumansInterleukin-12Interleukin-6Lymphocyte Activation Gene 3 ProteinMaleMembrane ProteinsAntigens, CDBiomarkersCA-125 AntigenCCL23 protein, humanChemokines, CCInterleukin-12Interleukin-6Lymphocyte Activation Gene 3 ProteinMembrane ProteinsMUC16 protein, humanProcalcitoninSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID34608231
PMCPMC8490434
OpenAlexW3202462577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.